{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T09:36:24Z","timestamp":1793007384081,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00213-026-07149-x","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:04:01Z","timestamp":1787112241000},"page":"2649-2668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Behavioral pharmacology of isolated cannabidiol in animal models of autism spectrum disorder: a systematic review"],"prefix":"10.1007","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6837-6272","authenticated-orcid":false,"given":"Iara K\u00e9ssila Milhome","family":"Vasconcelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8921-9341","authenticated-orcid":false,"given":"Maria Helena","family":"da Silva Pitombeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5111-7851","authenticated-orcid":false,"given":"David Ribeiro","family":"Fontenele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2128-5749","authenticated-orcid":false,"given":"Quezia Damaris Jones Severino","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-8371","authenticated-orcid":false,"given":"Gislei Frota","family":"Arag\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"7149_CR1","doi-asserted-by":"publisher","unstructured":"Ali F, Shehzad A, Shahzad R, Khan S, Rashan L, Taha M (2025) Cannabis oil protects against valproic acid-induced autism spectrum disorder by reducing oxidative stress. Dev Neurobiol 85:e22969. https:\/\/doi.org\/10.1002\/dneu.22969.","DOI":"10.1002\/dneu.22969."},{"key":"7149_CR2","doi-asserted-by":"publisher","unstructured":"Aljeaid M, Qashta A, Jalal Z, Jones AM (2025) Metabolic and endocrine ADRs of atypical antipsychotics (AAPs) in paediatric patients with autism spectrum disorder (ASD): a review of prevalence, risk factors, and implications for clinical monitoring. J Clin Med 14:7942. https:\/\/doi.org\/10.3390\/jcm14227942.","DOI":"10.3390\/jcm14227942."},{"key":"7149_CR3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders: DSM-5-TR. 5th edn, text rev. American Psychiatric Association Publishing, Washington, DC.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"7149_CR4","doi-asserted-by":"publisher","unstructured":"Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E (2019) Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study. J Autism Dev Disord 49:1284\u20131288. https:\/\/doi.org\/10.1007\/s10803-018-3808-2.","DOI":"10.1007\/s10803-018-3808-2."},{"key":"7149_CR5","doi-asserted-by":"publisher","unstructured":"Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, Shmueli D, Golan D, Castellanos FX (2021) Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism 12:6. https:\/\/doi.org\/10.1186\/s13229-021-00420-2.","DOI":"10.1186\/s13229-021-00420-2."},{"key":"7149_CR6","doi-asserted-by":"publisher","unstructured":"Atalay S, Jarocka-Karpowicz I, Skrzydlewska E (2019) Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel) 9:21. https:\/\/doi.org\/10.3390\/antiox9010021.","DOI":"10.3390\/antiox9010021."},{"key":"7149_CR7","doi-asserted-by":"publisher","unstructured":"Awad R, Aga-Mizrachi S, Maoz I, Simchi L, Avital A, Sosnik A (2026) Nose-to-brain administration of cannabidiol-loaded polymeric micelles improves the core behavioral symptoms of autism spectrum disorder. Bioact Mater 62:831\u2013845. https:\/\/doi.org\/10.1016\/j.bioactmat.2026.03.019.","DOI":"10.1016\/j.bioactmat.2026.03.019."},{"key":"7149_CR8","doi-asserted-by":"publisher","unstructured":"Azarfarin M, Ghadiri T, Dadkhah M, Sahab-Negah S (2024) The interaction between cannabinoids and long-term synaptic plasticity: a survey on memory formation and underlying mechanisms. Cell Biochem Funct 42:e4100. https:\/\/doi.org\/10.1002\/cbf.4100.","DOI":"10.1002\/cbf.4100."},{"key":"7149_CR9","doi-asserted-by":"publisher","unstructured":"Banker SM, Gu X, Schiller D, Foss-Feig JH (2021) Hippocampal contributions to social and cognitive deficits in autism spectrum disorder. Trends Neurosci 44:793\u2013807. https:\/\/doi.org\/10.1016\/j.tins.2021.08.005.","DOI":"10.1016\/j.tins.2021.08.005."},{"key":"7149_CR10","doi-asserted-by":"publisher","unstructured":"Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, Koren G, Berkovitch M (2019) Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol 9:1521. https:\/\/doi.org\/10.3389\/fphar.2018.01521.","DOI":"10.3389\/fphar.2018.01521."},{"key":"7149_CR11","doi-asserted-by":"publisher","unstructured":"Brigida AL, Schultz S, Cascone M, Antonucci N, Siniscalco D (2017) Endocannabinoid signal dysregulation in autism spectrum disorders: a correlation link between inflammatory state and neuro-immune alterations. Int J Mol Sci 18:1425. https:\/\/doi.org\/10.3390\/ijms18071425.","DOI":"10.3390\/ijms18071425."},{"key":"7149_CR12","doi-asserted-by":"publisher","unstructured":"Calapai F, Cardia L, Calapai G, Di Mauro D, Trimarchi F, Ammendolia I, Mannucci C (2022) Effects of cannabidiol on locomotor activity. https:\/\/doi.org\/10.3390\/life12050652.","DOI":"10.3390\/life12050652."},{"key":"7149_CR13","doi-asserted-by":"publisher","unstructured":"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, Hartmann-Boyce J, Ryan R, Shepperd S, Thomas J, Welch V, Thomson H (2020) Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 368:l6890. https:\/\/doi.org\/10.1136\/bmj.l6890.","DOI":"10.1136\/bmj.l6890."},{"key":"7149_CR14","doi-asserted-by":"publisher","unstructured":"Campos AC, Foga\u00e7a MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV, Sonego AB, Rodrigues NS, Galve-Roperh I, Guimar\u00e3es FS (2016) Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Front Pharmacol 7:269. https:\/\/doi.org\/10.3389\/fphar.2016.00269","DOI":"10.3389\/fphar.2016.00269"},{"key":"7149_CR15","doi-asserted-by":"publisher","unstructured":"Carrasco M, Volkmar FR, Bloch MH (2012) Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias. Pediatrics 129:e1301-e1310. https:\/\/doi.org\/10.1542\/peds.2011-3285.","DOI":"10.1542\/peds.2011-3285."},{"key":"7149_CR16","doi-asserted-by":"publisher","unstructured":"Chakrabarti B, Persico A, Battista N, Maccarrone M (2015) Endocannabinoid signaling in autism. Neurotherapeutics 12:837\u2013847. https:\/\/doi.org\/10.1007\/s13311-015-0371-9.","DOI":"10.1007\/s13311-015-0371-9."},{"key":"7149_CR17","doi-asserted-by":"publisher","unstructured":"Costa MA, Fernandes GZ, Maiochi E, Ebs MFP, Dar\u00f3s FS, Bolan SJ, Costa RRN, Rezende VL, Silva GC, Bitencourt RM, Gon\u00e7alves CL (2025) Effects of cannabidiol isolated or in association with risperidone in an animal model of autism. Dev Neurobiol 85:e22955. https:\/\/doi.org\/10.1002\/dneu.22955.","DOI":"10.1002\/dneu.22955."},{"key":"7149_CR18","doi-asserted-by":"publisher","unstructured":"Costa KCM, Brigante TAV, Lirio PHC, Fernandes GG, Scarante FF, Scomparin DSS, Ferreira RR, Vicente MA, Abe FR, Guimar\u00e3es FS, Hallak JEC, Crippa JA, de Oliveira DP, Campos AC (2025) Comparative analysis of cannabidiol and risperidone on behavioral and neurochemical outcomes, and neurodevelopment markers in a zebrafish model of embryonic exposure to sodium valproate. Autism Res 18:2368\u20132381. https:\/\/doi.org\/10.1002\/aur.70151.","DOI":"10.1002\/aur.70151."},{"key":"7149_CR19","doi-asserted-by":"publisher","unstructured":"Courchesne E (2004) Brain development in autism: early overgrowth followed by premature arrest of growth. Ment Retard Dev Disabil Res Rev 10:106\u2013111. https:\/\/doi.org\/10.1002\/mrdd.20020","DOI":"10.1002\/mrdd.20020"},{"key":"7149_CR20","doi-asserted-by":"publisher","unstructured":"De Almeida DL, Devi LA (2020) Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect 8:e00682. https:\/\/doi.org\/10.1002\/prp2.682.","DOI":"10.1002\/prp2.682."},{"key":"7149_CR21","doi-asserted-by":"publisher","unstructured":"De Oliveira CA, Iorio EL, Esp\u00edndola FS (2025) Redox system dysfunction as a key mechanism in autism spectrum disorder pathogenesis. Int J Mol Sci 26:9850. https:\/\/doi.org\/10.3390\/ijms26209850.","DOI":"10.3390\/ijms26209850."},{"key":"7149_CR22","doi-asserted-by":"publisher","unstructured":"Di Marzo V (2020) The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders. Dialogues Clin Neurosci 22:259\u2013269. https:\/\/doi.org\/10.31887\/DCNS.2020.22.3\/vdimarzo","DOI":"10.31887\/DCNS.2020.22.3\/vdimarzo"},{"key":"7149_CR23","doi-asserted-by":"publisher","unstructured":"Dorsey SG, Mocci E, Lane MV et al (2024) Rapid effects of valproic acid on the fetal brain transcriptome: implications for brain development and autism. Transl Psychiatry 14:482. https:\/\/doi.org\/10.1038\/s41398-024-03179-1.","DOI":"10.1038\/s41398-024-03179-1."},{"key":"7149_CR24","doi-asserted-by":"publisher","unstructured":"Ecker C, Bookheimer SY, Murphy DGM (2015) Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan. Lancet Neurol 14:1121\u20131134. https:\/\/doi.org\/10.1016\/S1474-4422(15)00050-2.","DOI":"10.1016\/S1474-4422(15)00050-2."},{"key":"7149_CR25","unstructured":"Elbe D, Lalani Z (2012) Review of the pharmacotherapy of irritability of autism. J Can Acad Child Adolesc Psychiatry 21:130\u2013146."},{"key":"7149_CR26","doi-asserted-by":"publisher","unstructured":"Foga\u00e7a MV, Campos AC, Coelho LD, Duman RS, Guimar\u00e3es FS (2018) The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling. Neuropharmacology 135:22\u201333. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.03.001.","DOI":"10.1016\/j.neuropharm.2018.03.001."},{"key":"7149_CR27","doi-asserted-by":"publisher","unstructured":"Gandhi T, Lee CC (2021) Neural mechanisms underlying repetitive behaviors in rodent models of autism spectrum disorders. Front Cell Neurosci 14:592710. https:\/\/doi.org\/10.3389\/fncel.2020.592710.","DOI":"10.3389\/fncel.2020.592710."},{"key":"7149_CR28","doi-asserted-by":"publisher","unstructured":"Hacohen M, Stolar OE, Berkovitch M, Elkana O, Kohn E, Hazan A, Heyman E, Sobol Y, Waissengreen D, Gal E, Dinstein I (2022) Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study. Transl Psychiatry 12:375. https:\/\/doi.org\/10.1038\/s41398-022-02104-8.","DOI":"10.1038\/s41398-022-02104-8."},{"key":"7149_CR29","doi-asserted-by":"publisher","unstructured":"Hashem E, Ariza J, Rogers H, Noctor SC, Mart\u00ednez-Cerde\u00f1o V (2017) The number of parvalbumin-expressing interneurons is decreased in the prefrontal cortex in autism. Cereb Cortex 27:1931\u20131943. https:\/\/doi.org\/10.1093\/cercor\/bhw021.","DOI":"10.1093\/cercor\/bhw021."},{"key":"7149_CR30","doi-asserted-by":"publisher","unstructured":"Hazlett HC, Poe MD, Gerig G, Styner M, Chappell C, Smith RG, Vachet C, Piven J (2011) Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. Arch Gen Psychiatry 68:467\u2013476. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.39.","DOI":"10.1001\/archgenpsychiatry.2011.39."},{"key":"7149_CR31","doi-asserted-by":"publisher","unstructured":"Hooijmans CR, Rovers MM, De Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW (2014) SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol 14:43. https:\/\/doi.org\/10.1186\/1471-2288-14-43.","DOI":"10.1186\/1471-2288-14-43."},{"key":"7149_CR32","doi-asserted-by":"publisher","unstructured":"Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2:139\u2013154. https:\/\/doi.org\/10.1089\/can.2016.0034.","DOI":"10.1089\/can.2016.0034."},{"key":"7149_CR33","doi-asserted-by":"publisher","unstructured":"Jiang YH, Ehlers MD (2013) Modeling autism by SHANK gene mutations in mice. Neuron 78:8\u201327. https:\/\/doi.org\/10.1016\/j.neuron.2013.03.016.","DOI":"10.1016\/j.neuron.2013.03.016."},{"key":"7149_CR34","doi-asserted-by":"publisher","unstructured":"Juarez P, Mart\u00ednez-Cerde\u00f1o V (2022) Parvalbumin and parvalbumin chandelier interneurons in autism and other psychiatric disorders. Front Psychiatry 13:913550. https:\/\/doi.org\/10.3389\/fpsyt.2022.913550.","DOI":"10.3389\/fpsyt.2022.913550."},{"key":"7149_CR35","doi-asserted-by":"publisher","unstructured":"Kaplan JS, Wagner JK, Reid K, McGuinness F, Arvila S, Brooks M, Stevenson H, Jones J, Risch B, McGillis T, Budinich R, Gambell E, Predovich B (2021) Cannabidiol exposure during the mouse adolescent period is without harmful behavioral effects on locomotor activity, anxiety, and spatial memory. Front Behav Neurosci 15:711639. https:\/\/doi.org\/10.3389\/fnbeh.2021.711639.","DOI":"10.3389\/fnbeh.2021.711639."},{"key":"7149_CR36","doi-asserted-by":"publisher","unstructured":"Kerr DM, Downey L, Conboy M, Finn DP, Roche M (2013) Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res 249:124\u2013132. https:\/\/doi.org\/10.1016\/j.bbr.2013.04.043.","DOI":"10.1016\/j.bbr.2013.04.043."},{"key":"7149_CR37","doi-asserted-by":"publisher","unstructured":"Kicman A, Toczek M (2020) The effects of cannabidiol, a non-intoxicating compound of cannabis, on the cardiovascular system in health and disease. Int J Mol Sci 21:6740. https:\/\/doi.org\/10.3390\/ijms21186740.","DOI":"10.3390\/ijms21186740."},{"key":"7149_CR38","doi-asserted-by":"publisher","unstructured":"Lai MC, Lombardo MV, Auyeung B, Chakrabarti B, Baron-Cohen S (2015) Sex\/gender differences and autism: setting the scene for future research. J Am Acad Child Adolesc Psychiatry 54:11\u201324. https:\/\/doi.org\/10.1016\/j.jaac.2014.10.003.","DOI":"10.1016\/j.jaac.2014.10.003."},{"key":"7149_CR39","doi-asserted-by":"publisher","unstructured":"Licitra R, Damiani D, Naef V, Fronte B, Della Vecchia S, Sangiacomo C, Marchese M, Santorelli FM (2023) Cannabidiol mitigates valproic acid-induced developmental toxicity and locomotor behavioral impairment in zebrafish. J Biol Regul Homeost Agents 37:4935\u20134946. https:\/\/doi.org\/10.23812\/j.biol.regul.homeost.agents.20233709.480.","DOI":"10.23812\/j.biol.regul.homeost.agents.20233709.480."},{"key":"7149_CR40","doi-asserted-by":"publisher","unstructured":"Liu X, Lin J, Zhang H, Khan NU, Zhang J, Tang X, Cao X, Shen L (2022) Oxidative stress in autism spectrum disorder-current progress of mechanisms and biomarkers. Front Psychiatry 13:813304. https:\/\/doi.org\/10.3389\/fpsyt.2022.813304.","DOI":"10.3389\/fpsyt.2022.813304."},{"key":"7149_CR41","doi-asserted-by":"publisher","unstructured":"Loomes R, Hull L, Mandy WPL (2017) What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 56:466\u2013474. https:\/\/doi.org\/10.1016\/j.jaac.2017.03.013.","DOI":"10.1016\/j.jaac.2017.03.013."},{"key":"7149_CR42","doi-asserted-by":"publisher","unstructured":"Mabunga DFN, Gonzales ELT, Kim JW, Kim KC, Shin CY (2015) Exploring the validity of valproic acid animal model of autism. Exp Neurobiol 24:285\u2013300. https:\/\/doi.org\/10.5607\/en.2015.24.4.285.","DOI":"10.5607\/en.2015.24.4.285."},{"key":"7149_CR43","doi-asserted-by":"publisher","unstructured":"Macleod MR, O\u2019Collins T, Howells DW, Donnan GA (2004) Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35:1203\u20131208. https:\/\/doi.org\/10.1161\/01.STR.0000125719.25853.20.","DOI":"10.1161\/01.STR.0000125719.25853.20."},{"key":"7149_CR44","doi-asserted-by":"publisher","unstructured":"Martinez Naya N, Kelly J, Corna G, Golino M, Polizio AH, Abbate A, Toldo S, Mezzaroma E (2024) An overview of cannabidiol as a multifunctional drug: pharmacokinetics and cellular effects. Molecules 29:473. https:\/\/doi.org\/10.3390\/molecules29020473.","DOI":"10.3390\/molecules29020473."},{"key":"7149_CR45","doi-asserted-by":"publisher","unstructured":"Masini E, Loi E, Vega-Benedetti AF, Carta M, Doneddu G, Fadda R, Zavattari P (2020) An overview of the main genetic, epigenetic and environmental factors involved in autism spectrum disorder focusing on synaptic activity. Int J Mol Sci 21:8290. https:\/\/doi.org\/10.3390\/ijms21218290.","DOI":"10.3390\/ijms21218290."},{"key":"7149_CR46","doi-asserted-by":"publisher","unstructured":"Mediane DH, Basu S, Cahill EN, Anastasiades PG (2024) Medial prefrontal cortex circuitry and social behaviour in autism. Neuropharmacology 260:110101. https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110101.","DOI":"10.1016\/j.neuropharm.2024.110101."},{"key":"7149_CR47","doi-asserted-by":"publisher","unstructured":"Melancia F, Schiavi S, Servadio M, Cartocci V, Campolongo P, Palmery M, Pallottini V, Trezza V (2018) Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling. Br J Pharmacol 175:3699\u20133712. https:\/\/doi.org\/10.1111\/bph.14435.","DOI":"10.1111\/bph.14435."},{"key":"7149_CR49","doi-asserted-by":"publisher","unstructured":"Meyza KZ, Defensor EB, Jensen AL, Corley MJ, Pearson BL, Pobbe RLH, Bolivar VJ, Blanchard DC, Blanchard RJ (2013) The BTBR T\u2009+\u2009tf\/J mouse model for autism spectrum disorders-in search of biomarkers. Behav Brain Res 251:25\u201334. https:\/\/doi.org\/10.1016\/j.bbr.2012.07.021.","DOI":"10.1016\/j.bbr.2012.07.021."},{"key":"7149_CR48","doi-asserted-by":"publisher","unstructured":"Meza N, Rees R, Escobar Liquitay CM, Franco JVA, Sguassero Y, Williams K, Pringsheim T, Rojas V, Madrid E (2022) Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. Cochrane Database Syst Rev 2022:CD014965. https:\/\/doi.org\/10.1002\/14651858.CD014965.","DOI":"10.1002\/14651858.CD014965."},{"key":"7149_CR50","doi-asserted-by":"publisher","unstructured":"Nelson SB, Valakh V (2015) Excitatory\/inhibitory balance and circuit homeostasis in autism spectrum disorders. Neuron 87:684\u2013698. https:\/\/doi.org\/10.1016\/j.neuron.2015.07.033.","DOI":"10.1016\/j.neuron.2015.07.033."},{"key":"7149_CR51","doi-asserted-by":"publisher","unstructured":"Nicolini C, Fahnestock M (2018) The valproic acid-induced rodent model of autism. Exp Neurol 299:217\u2013227. https:\/\/doi.org\/10.1016\/j.expneurol.2017.04.017.","DOI":"10.1016\/j.expneurol.2017.04.017."},{"key":"7149_CR52","doi-asserted-by":"publisher","unstructured":"Osborne AL, Solowij N, Babic I, Huang XF, Weston-Green K (2017) Improved social interaction, recognition and working memory with cannabidiol treatment in a prenatal infection (poly I:C) rat model. Neuropsychopharmacology 42:1447\u20131457. https:\/\/doi.org\/10.1038\/npp.2017.40.","DOI":"10.1038\/npp.2017.40."},{"key":"7149_CR53","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10:89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","DOI":"10.1186\/s13643-021-01626-4."},{"key":"7149_CR54","doi-asserted-by":"publisher","unstructured":"Patricio F, Morales-Andrade AA, Patricio-Mart\u00ednez A, Lim\u00f3n ID (2020) Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson\u2019s disease. Front Pharmacol 11:595635. https:\/\/doi.org\/10.3389\/fphar.2020.595635.","DOI":"10.3389\/fphar.2020.595635."},{"key":"7149_CR55","unstructured":"Pay\u00e1 Gonz\u00e1lez B, Fuentes Menchaca N. Neurobiology of autism: neuropathology and neuroimaging studies. Actas Esp Psiquiatr. 2007 Jul-Aug;35(4):271-6."},{"key":"7149_CR57","doi-asserted-by":"publisher","unstructured":"Pe\u00e7a J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN, Lascola CD, Fu Z, Feng G (2011) Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472:437\u2013442. https:\/\/doi.org\/10.1038\/nature09965.","DOI":"10.1038\/nature09965."},{"key":"7149_CR56","doi-asserted-by":"publisher","unstructured":"Pedrazzi JFC, Sales AJ, Ponciano RSM, Ferreira LG, Ferreira FR, Campos AC, Hallak JEC, Zuardi AW, Del Bel EA, Guimar\u00e3es FS, Crippa J (2025) Acute cannabidiol treatment reverses behavioral impairments induced by embryonic valproic acid exposure in male mice. Pharmacol Biochem Behav 247:173919. https:\/\/doi.org\/10.1016\/j.pbb.2024.173919.","DOI":"10.1016\/j.pbb.2024.173919."},{"key":"7149_CR58","doi-asserted-by":"publisher","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol 18:e3000410. https:\/\/doi.org\/10.1371\/journal.pbio.3000410.","DOI":"10.1371\/journal.pbio.3000410."},{"key":"7149_CR59","doi-asserted-by":"publisher","unstructured":"Pereira SR, Hackett B, O\u2019Driscoll DN, Sun MC, Downer EJ (2021) Cannabidiol modulation of oxidative stress and signalling. Neuronal Signal 5:NS20200080. https:\/\/doi.org\/10.1042\/NS20200080.","DOI":"10.1042\/NS20200080."},{"key":"7149_CR60","doi-asserted-by":"publisher","unstructured":"Poleg S, Kourieh E, Ruban A, Shapira G, Shomron N, Barak B, Offen D (2021) Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder. Transl Psychiatry 11:524. https:\/\/doi.org\/10.1038\/s41398-021-01612-3.","DOI":"10.1038\/s41398-021-01612-3."},{"key":"7149_CR61","doi-asserted-by":"publisher","unstructured":"Resstel LBM, Tavares RF, Lisboa SFS, Joca SRL, Corr\u00eaa FMA, Guimar\u00e3es FS (2009) 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156:181\u2013188. https:\/\/doi.org\/10.1111\/j.1476-5381.2008.00046.x.","DOI":"10.1111\/j.1476-5381.2008.00046.x."},{"key":"7149_CR62","doi-asserted-by":"publisher","unstructured":"Rossignol DA, Frye RE (2014) Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism. Front Physiol 5:150. https:\/\/doi.org\/10.3389\/fphys.2014.00150.","DOI":"10.3389\/fphys.2014.00150."},{"key":"7149_CR64","doi-asserted-by":"publisher","unstructured":"Russo EB (2019) The case for the entourage effect and conventional breeding of clinical cannabis: no \u201cstrain,\u201d no gain. Front Plant Sci 9:1969. https:\/\/doi.org\/10.3389\/fpls.2018.01969.","DOI":"10.3389\/fpls.2018.01969."},{"key":"7149_CR63","doi-asserted-by":"publisher","unstructured":"Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163:1344\u20131364. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01238.x.","DOI":"10.1111\/j.1476-5381.2011.01238.x."},{"key":"7149_CR65","doi-asserted-by":"crossref","unstructured":"Sauer AK, Stanton JE, Hans S, Grabrucker AM (2021) Autism spectrum disorders: etiology and pathology. In: Grabrucker AM (ed) Autism spectrum disorders. Exon Publications, Brisbane","DOI":"10.36255\/exonpublications.autismspectrumdisorders.2021.etiology"},{"key":"7149_CR66","doi-asserted-by":"publisher","unstructured":"Seeman P (2016) Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry 6:e920. https:\/\/doi.org\/10.1038\/tp.2016.195.","DOI":"10.1038\/tp.2016.195."},{"key":"7149_CR67","doi-asserted-by":"publisher","unstructured":"Servadio M, Melancia F, Manduca A, Di Masi A, Schiavi S, Cartocci V, Pallottini V, Campolongo P, Ascenzi P, Trezza V (2016) Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. Transl Psychiatry 6:e902. https:\/\/doi.org\/10.1038\/tp.2016.182.","DOI":"10.1038\/tp.2016.182."},{"key":"7149_CR70","doi-asserted-by":"publisher","unstructured":"Shrader SH, Mellen J, Cai N, Barnes GN, Song ZH (2024) Cannabidiol is a behavioral modulator in BTBR mouse model of idiopathic autism. Front Neurosci 18:1359810. https:\/\/doi.org\/10.3389\/fnins.2024.1359810.","DOI":"10.3389\/fnins.2024.1359810."},{"key":"7149_CR71","doi-asserted-by":"publisher","unstructured":"Shrader SH, Tong YG, Duff MB, Freedman JH, Song ZH (2020) Involvement of dopamine receptor in the actions of non-psychoactive phytocannabinoids. Biochem Biophys Res Commun 533:1366\u20131370. https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.021.","DOI":"10.1016\/j.bbrc.2020.10.021."},{"key":"7149_CR68","doi-asserted-by":"publisher","unstructured":"Silva Junior EA, Medeiros WMB, Santos JPM, Sousa JMM, Costa FB, Pontes KM, Borges TC, Neto Segundo CE, Andrade e Silva AH, Nunes ELG, Alves NT, Rosa MD, Albuquerque KLGD (2024) Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. Trends Psychiatry Psychother 46:e20210396. https:\/\/doi.org\/10.47626\/2237-6089-2021-0396.","DOI":"10.47626\/2237-6089-2021-0396."},{"key":"7149_CR69","doi-asserted-by":"publisher","unstructured":"Silverman JL, Thurm A, Ethridge SB, Soller MM, Petkova SP, Abel T, et al (2022) Reconsidering animal models used to study autism spectrum disorder: current state and optimizing future. Genes Brain Behav 21:e12803. https:\/\/doi.org\/10.1111\/gbb.12803.","DOI":"10.1111\/gbb.12803."},{"key":"7149_CR72","doi-asserted-by":"publisher","unstructured":"Tian J, Gao X, Yang L (2022) Repetitive restricted behaviors in autism spectrum disorder: from mechanism to development of therapeutics. Front Neurosci 16:780407. https:\/\/doi.org\/10.3389\/fnins.2022.780407.","DOI":"10.3389\/fnins.2022.780407."},{"key":"7149_CR73","doi-asserted-by":"publisher","unstructured":"Uchino S, Waga C (2013) SHANK3 as an autism spectrum disorder-associated gene. Brain Dev 35:106\u2013110. https:\/\/doi.org\/10.1016\/j.braindev.2012.05.013.","DOI":"10.1016\/j.braindev.2012.05.013."},{"key":"7149_CR74","doi-asserted-by":"publisher","unstructured":"Udodi PS, Agu AU, Johnson N, Udodi RE, Anyanwu CN, Anyanwu GE (2025) Cannabidiol alleviates valproic acid-induced developmental changes in mice pups: role of the allosteric modulation of the CB1 receptor in the regulation of the GABAergic system. Neurosci Behav Physiol 55. https:\/\/doi.org\/10.1007\/s11055-025-01754-7.","DOI":"10.1007\/s11055-025-01754-7."},{"key":"7149_CR75","doi-asserted-by":"publisher","unstructured":"Usui N, Kobayashi H, Shimada S (2023) Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder. Int J Mol Sci 24:5487. https:\/\/doi.org\/10.3390\/ijms24065487.","DOI":"10.3390\/ijms24065487."},{"key":"7149_CR76","doi-asserted-by":"publisher","unstructured":"Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, Gall CM, Piomelli D (2016) Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment. Cannabis Cannabinoid Res 1:81\u201389. https:\/\/doi.org\/10.1089\/can.2015.0008.","DOI":"10.1089\/can.2015.0008."},{"key":"7149_CR77","doi-asserted-by":"publisher","unstructured":"Wei D, Lee D, Cox CD, Karsten CA, Pe\u00f1agarikano O, Geschwind DH, Gall CM, Piomelli D (2015) Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S A 112:14084\u201314089. https:\/\/doi.org\/10.1073\/pnas.1509795112.","DOI":"10.1073\/pnas.1509795112."},{"key":"7149_CR78","doi-asserted-by":"publisher","unstructured":"Werling DM, Geschwind DH (2013) Sex differences in autism spectrum disorders. Curr Opin Neurol 26:146\u2013153. https:\/\/doi.org\/10.1097\/WCO.0b013e32835ee548.","DOI":"10.1097\/WCO.0b013e32835ee548."},{"key":"7149_CR79","doi-asserted-by":"publisher","unstructured":"Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O\u2019Shea DJ, Sohal VS, Goshen I, Finkelstein J, Paz JT, Stehfest K, Fudim R, Ramakrishnan C, Huguenard JR, Hegemann P, Deisseroth K (2011) Neocortical excitation\/inhibition balance in information processing and social dysfunction. Nature 477:171\u2013178. https:\/\/doi.org\/10.1038\/nature10360.","DOI":"10.1038\/nature10360."},{"key":"7149_CR80","doi-asserted-by":"publisher","unstructured":"Zamberletti E, Gabaglio M, Parolaro D (2017) The endocannabinoid system and autism spectrum disorders: insights from animal models. Int J Mol Sci 18:1916. https:\/\/doi.org\/10.3390\/ijms18091916","DOI":"10.3390\/ijms18091916"},{"key":"7149_CR81","doi-asserted-by":"publisher","unstructured":"Zarate-Lopez D, Torres-Ch\u00e1vez AL, G\u00e1lvez-Contreras AY, Gonzalez-Perez O (2024) Three decades of valproate: a current model for studying autism spectrum disorder. Curr Neuropharmacol 22:260\u2013289. https:\/\/doi.org\/10.2174\/1570159X22666231003121513.","DOI":"10.2174\/1570159X22666231003121513."},{"key":"7149_CR82","doi-asserted-by":"publisher","unstructured":"Zhuang H, Liang Z, Ma G, Qureshi A, Ran X, Feng C, Liu X, Yan X, Shen L (2024) Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy. MedComm (2020) 5:e497. https:\/\/doi.org\/10.1002\/mco2.497.","DOI":"10.1002\/mco2.497."},{"key":"7149_CR83","doi-asserted-by":"publisher","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimar\u00e3es FS, Crippa JAS (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259. https:\/\/doi.org\/10.3389\/fphar.2017.00259.","DOI":"10.3389\/fphar.2017.00259."}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07149-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T09:09:18Z","timestamp":1793005758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07149-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":83,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["7149"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07149-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this review the authors used ChatGPT-5 to correct grammar, improve the text cohesion, and syntax. All authors reviewed the final version and take full responsibility for the content of this publication.","order":1,"name":"Ethics","label":"Declaration of Generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}